Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer

Annals of Oncology

Volumn 20, Issue 6, 2009, Pages 993-999

  Buzdar, A U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Chemotherapy; Estrogen receptor; HER2; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FULVESTRANT; HYDROXYTAMOXIFEN; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BIOLOGICAL THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 66149155038     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn739     Document Type: Review

References (44)

1. Winer EP. Optimizing endocrine therapy for breast cancer. J Clin Oncol 2005; 8: 1609-1610.
2. Buzdar A, Howell A. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620-2635.
3. Dowsett M. Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin Oncol 2003; 30 (Suppl 14): 58-69.
4. Mouridsen HT, Rose C, Brodie AH et al. Challenges in the endocrine management of breast cancer. Breast 2003; 12 (Suppl 2): S2-S19.
5. Osbourne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-361.
6. Strasser-Weippl K, Goss PE. Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 2005; 23: 1751-1759.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
8. Carlson RW (Panel chair). NCCN Practice Guidelines in Oncology. Breast cancer. v.2.2008. http://www.nccn.org/professionals/physician_gls/PDF/ breast.pdf (last accessed November 2008).
9. Carlson RW, Brown E, Burstein HJ et al. NCCN Task Force Report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006; 4 (Suppl 1): S1-S26.
10. Buzdar AU, Valero V, Ibrahim NK et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13: 228-233.
11. Spicer J, Ellis P. Towards optimal endocrine therapy for hormone-sensitive breast cancer: Initial versus sequential adjuvant aromatase inhibition. Cancer Lett 2007; 248: 165-174.
12. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
13. Breast International (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
14. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
15. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
16. Lipton A, Ali SM, Leitzel K et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20: 1467-1472.
17. Read LD, Keith D, Slamon DJ et al. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p1875 protein expression in human breast cancer cell lines. Cancer Res 1990; 50: 3947-3951.
18. Liu Y, el-Ashry D, Chen D et al. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 1995; 34: 97-117.
19. Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-2446.
20. Bunone G, Briand PA, Miksicek RJ et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174-2183.
21. Arpino G, Green SJ, Allred C et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. Clin Cancer Res 2004; 10: 5670-5676.
22. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63: 6523-6531.
23. Ellis MJ, Tao Y, Young O et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006; 24: 3019-3025.
24. Dowsett M, Allred DC. on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006; 100 (Suppl 1): S21 (Abstr 48).
25. Rasmussen BB, Regan MM, Lykkesfeldt AE et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9: 23-28.
26. Knoop AS, Bentzen SM, Nielsen MM et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19: 3376-3384.
27. Berry DA, Muss HB, Thor AD et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18: 3471-4347.
28. Mackey JR, Kaufman B, Clemens M et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1): S5 (Abstr 3).
29. Marcom PK, Isaacs C, Harris L et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of Her2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007; 102: 43-49.
30. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
31. Sabnis GJ, Brodie AM. Trastuzumab improves the responsiveness of letrozole refractory human breast cancer cells to endocrine therapy. Breast Cancer Res Treat 2006; 100 (Suppl 1): S26.
32. Leary AF, Martin LA, Lykkesfekdt AE et al. Enhancing endocrine responsiveness using the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in cell models of endocrine resistance. Breast Cancer Res Treat 2006; 100 (Suppl 1): S5 (Abstr 303).
33. Emde AM, Maslak K, Liu H et al. Combination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell lines. J Clin Oncol 2007; 25 (Suppl): 6s (Abstr 14050).
34. Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003; 21: 1967-1972.
35. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
36. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
37. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
38. Semiglazov VF, Semiglazov VV, Dashyan GA et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007; 110: 244-254.
39. The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: Results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 2007; 99: 516-525.
40. Love RR, Dinh NV, Quy TT et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 2008; 26: 253-257.
41. Brufsky A, Lembersky B, Schiffman K et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 2005; 6: 247-252.
42. Perez EA, Romond EH, Suman VJ et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/ without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25 (Suppl): 6s (Abstr 512).
43. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet 2007; 369: 29-36.
44. Buzdar AU. Aromatase inhibitors: Changing the face of endocrine therapy for breast cancer. Breast Dis 2005-2006; 24: 107-117.